Celcuity’s Breast Cancer Drug Outperforms Rivals at ASCO, Yet Wall Street Still Reacts Negatively

Celcuity’s gedatolisib doubled progression-free survival (11.1 vs 5.6 months) compared with Novartis’ Piqray in a Phase 3 breast cancer trial presented at ASCO 2026, but fell short of high market expectations.